Arisyn Therapeutics

Arisyn Therapeutics is a clinical-stage biotechnology company focused on developing novel small molecule therapies for cancer and infectious diseases. The company's lead candidate, ATI-0810 (also known as AR-12), is a first-in-class derivative of celecoxib that inhibits PDK1 and the molecular chaperone GRP78. This dual mechanism of action induces endoplasmic reticulum stress and autophagy, leading to apoptosis in malignant cells and the inhibition of viral and bacterial replication. Arisyn is currently exploring the potential of ATI-0810 in treating various solid tumors and hematologic malignancies. Additionally, the compound is being investigated as a broad-spectrum anti-infective agent due to its ability to disrupt host-cell mechanisms required by pathogens. The company aims to address significant unmet needs in oncology and global health through its targeted small molecule approach.